ZYBERNO
Stock Report
Updated Sep 1, 2026

Entera Bio Ltd. (ENTX)

Healthcare • NASDAQ

$2.95

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
37.0/100
WEAK BUSINESS
Entera Bio Ltd. (ENTX) scores 37/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-147.2%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-132.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Entera Bio Ltd. (ENTX) stock report — Zyberno Score 37/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ENTX generated -$9.08M in Owner Earnings. Capital was deployed as follows: $99.00K invested in capital expenditures. Reinvestment rate: -0.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.95
Market Cap:$507.21M

Valuation Multiples (3)

P/B Ratio:69.81x
Peg Ratio:0.27x

Enterprise Metrics (1)

Enterprise Value:$496.33M

Price Action & Momentum (3)

Momentum Percentile:31 / 100
% of 52-Week High:70.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-103.2%
Reinvestment Rate:-0.7%
Fundamental Growth Rate (g):0.9%

Margin Analysis (1)

Ebitda Margin:-34,216.7%

Yield Metrics (2)

Earnings Yield:$11.85
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:200.0%
Latest Earnings Filed:2026-08-07

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):19.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:8.98x
Quick Ratio:8.98x
Cash Ratio:5.38x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:16,792,000.00
Cash And Cash Equivalents:11,309,000.00
Long Term Debt:$226.00K
Net Debt:-$10.88M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $42.00K
Linear Growth: 19.3%
📊 Click to view full ENTX Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $0.00
Linear Growth: -1.8%
📊 Click to view full ENTX Gross Profit analysis & methodology →
-$14.40M

Bottom Line Performance (3)

-$17.03M
Income Before Tax:-$9.69M
Ebitda Ttm:-14,371,000.00

Operating Expenses (5)

Operating Expenses:14,400,000.00
R And D Expense:8,813,000.00
Sga Expense:5,587,000.00
Income Tax Expense:$29.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-34,216.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$19.48M
Current Assets:$18.90M
Ppe Net:121,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:12,214,000.00
Current Liabilities:2,104,000.00
Long Term Debt:$226.00K
Short Term Debt:$199.00K

Equity & Capital (3)

Equity:$7.27M
Retained Earnings:-$136.18M
Common Stock:140,010,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:575,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:672,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$9.06M-$9.16M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:99,000.00

Financing Activities (3)

Financing Cash Flow:$130.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:29,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.34
Eps diluted TTM: $0.34
Linear Growth: -5.3%
📊 Click to view full ENTX EPS analysis & methodology →
Earnings Per Share Ttm:-$0.10

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.04

Book Value & Capital (2)

Book Value Per Share:$0.04
Cash Per Share:0.07

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:4,997.02
Cash Conversion Cycle:-6,995.02
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$9.08M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.7%
Fundamental Growth Rate (g):0.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):19.3%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-1.8%
Book Value Growth Rate (Linear):-4.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:ENTX
Company Name:Entera Bio Ltd.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:171.94M
Shares Outstanding Basic:50.45M
Shares Outstanding Diluted:50.45M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 00:42:54 UTC
Data Timestamp:2026-08-20T05:56:56.808001
Scroll to Top